Modeling of catecholaminergic polymorphic ventricular tachycardia with patient-specific human-induced pluripotent stem cells.
about
Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes Afford New Opportunities in Inherited Cardiovascular Disease ModelinghiPSC-derived iMSCs: NextGen MSCs as an advanced therapeutically active cell resource for regenerative medicineBarth Syndrome: From Mitochondrial Dysfunctions Associated with Aberrant Production of Reactive Oxygen Species to Pluripotent Stem Cell StudiesInduced Pluripotency and Gene Editing in Disease Modelling: Perspectives and ChallengesInduced pluripotent stem cells for cardiovascular disease: from product-focused disease modeling to process-focused disease discoveryCardiovascular Disease Modeling Using Patient-Specific Induced Pluripotent Stem CellsInduced pluripotent stem cell-derived cardiomyocytes for cardiovascular disease modeling and drug screeningHighlights of the year in JACC 2012Calcium signalling of human pluripotent stem cell-derived cardiomyocytesA Systemized Approach to Investigate Ca(2+) Synchronization in Clusters of Human Induced Pluripotent Stem-Cell Derived CardiomyocytesPatient Specific Induced Pluripotent Stem Cell-Derived Cardiomyocytes for Drug Development and Screening In Catecholaminergic Polymorphic Ventricular TachycardiaInduced pluripotent stem cell potential in medicine, specifically focused on reproductive medicineModelling sarcomeric cardiomyopathies in the dish: from human heart samples to iPSC cardiomyocytesAntiarrhythmic Effects of Dantrolene in Patients with Catecholaminergic Polymorphic Ventricular Tachycardia and Replication of the Responses Using iPSC ModelsStem cell-derived models to improve mechanistic understanding and prediction of human drug-induced liver injuryCaMKII inhibition rectifies arrhythmic phenotype in a patient-specific model of catecholaminergic polymorphic ventricular tachycardia.Functional abnormalities in iPSC-derived cardiomyocytes generated from CPVT1 and CPVT2 patients carrying ryanodine or calsequestrin mutationsBiomaterials in cardiovascular research: applications and clinical implications.The Promise and Challenge of Induced Pluripotent Stem Cells for Cardiovascular Applications.From Bench to Market: Preparing Human Pluripotent Stem Cells Derived Cardiomyocytes for Various ApplicationsMyosin light chain 2-based selection of human iPSC-derived early ventricular cardiac myocytes.iPCS Cell Modeling of Inherited Cardiac Arrhythmias.Human stem cells for modeling heart disease and for drug discovery.A near-infrared fluorescent voltage-sensitive dye allows for moderate-throughput electrophysiological analyses of human induced pluripotent stem cell-derived cardiomyocytes.Monitoring Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes with Genetically Encoded Calcium and Voltage Fluorescent Reporters.Drug screening using a library of human induced pluripotent stem cell-derived cardiomyocytes reveals disease-specific patterns of cardiotoxicityNovel Analysis Software for Detecting and Classifying Ca2+ Transient Abnormalities in Stem Cell-Derived Cardiomyocytes.Patient-Specific Human Induced Pluripotent Stem Cell Model Assessed with Electrical Pacing Validates S107 as a Potential Therapeutic Agent for Catecholaminergic Polymorphic Ventricular Tachycardia.Finding the rhythm of sudden cardiac death: new opportunities using induced pluripotent stem cell-derived cardiomyocytesExtracellular Matrix-Mediated Maturation of Human Pluripotent Stem Cell-Derived Cardiac Monolayer Structure and Electrophysiological Function.Induced pluripotent stem cells in cardiovascular drug discovery.Generation of human cardiomyocytes: a differentiation protocol from feeder-free human induced pluripotent stem cellsModeling heart disease in a dish: from somatic cells to disease-relevant cardiomyocytes.Pluripotent stem cell models of human heart diseaseA human pluripotent stem cell model of catecholaminergic polymorphic ventricular tachycardia recapitulates patient-specific drug responses.Gene expression profiles in engineered cardiac tissues respond to mechanical loading and inhibition of tyrosine kinases.Adeno-associated virus-mediated CASQ2 delivery rescues phenotypic alterations in a patient-specific model of recessive catecholaminergic polymorphic ventricular tachycardia.Cardiomyocytes from human pluripotent stem cells: From laboratory curiosity to industrial biomedical platform.Patient-Specific Induced Pluripotent Stem Cell Models: Generation and Characterization of Cardiac CellsPatient-Specific and Genome-Edited Induced Pluripotent Stem Cell-Derived Cardiomyocytes Elucidate Single-Cell Phenotype of Brugada Syndrome.
P2860
Q26750618-536CAE78-1837-4C3D-B16E-0DF8F145CAB2Q26751506-0E52E454-9063-4E29-A527-CA393D35E79CQ26772690-06B4E522-FA0B-4D0E-B7A2-F4429D5CA38DQ26775061-D4FC111B-8963-4279-A5D9-86CE39FE1872Q26781825-982CA874-3501-4D71-ACE6-18E4FD254B68Q26798131-B0A01B57-FB08-44E4-A617-F4069E1F2AEEQ26828408-9206AD89-52E4-4F5C-9BC1-D76E21E323C3Q26865608-9A2787FD-30D2-4049-93F6-F0F28F9E395CQ27002443-EC67B073-3E73-4778-9B87-2ADB3B2DD152Q27330969-2D5E6F94-E065-4120-961B-B9C941B01354Q28067569-AA48D456-BA65-4E42-B2C6-F2EE95B5CC7AQ28083057-4C9712E6-9506-4532-B33E-2BF0E8186F95Q28255887-6B912092-604F-4246-93D8-8233F7D5E062Q28547114-C5A83C90-C93C-4AA2-A7FC-0A4059DE69CFQ28818235-F1D6CA42-430E-4491-B397-6F546E9373F0Q30557177-C50D577C-6A99-4214-857F-2C327171163FQ33165988-52DC5F8E-3386-4ED9-A356-5CAB61C882F5Q33660457-462CF00E-49AA-4CCF-9F04-3831F19820E9Q33748399-14B4E673-8A84-479B-B295-F88522228453Q33847517-E7D4582F-EEA5-4D16-AF3A-0F2A2C383562Q34103739-DB7D4C8A-DE7E-495F-9B2B-8905D6E234B6Q34431713-0FFE9D32-95DA-4557-82EF-255938010671Q34433363-E679682E-AC87-4479-92F5-5B219D5BEFC6Q34439974-D224BEAF-9BB6-45A8-A8CE-458D10B639B0Q34494232-C465BC9F-2351-4424-B14E-1F2684D5BEDBQ34631498-88419180-85A5-4F7F-A2B6-B98F151DCB78Q35755909-6E84777A-B2B9-4D24-B398-3FEA4375F2F9Q36169155-7EDAACD4-6FF2-440B-82A3-C2C33C1FE289Q36365384-F6AE5DF8-E33C-40F6-BD51-4D940919E924Q36801655-43223E24-D0AD-4B8A-A174-815C9DC416A9Q36996592-4B959DE6-93F1-4555-9243-0830E4203B2AQ37059614-61686A36-601D-4AAE-A9A6-9248273BD6ADQ37143372-BA31F661-206E-40FD-A606-DD6D366905DBQ37256433-2D8E807A-0EA7-432C-8E81-5EE19A58A5D4Q37305886-16B2618E-E62B-4AAC-8E8E-4ED869C877E0Q37344100-4312B4FF-52ED-4915-921A-124CE04FCBCAQ37465870-C38DA639-60AB-449E-AD59-A84CE0102426Q37573646-B776E79F-64BE-4D96-BD58-8A0D4671563EQ37710335-BA992E5E-07C5-4AA8-B003-5DD357A56E5CQ37730325-67295E85-53CC-4A05-9F8B-F4DA26CDB585
P2860
Modeling of catecholaminergic polymorphic ventricular tachycardia with patient-specific human-induced pluripotent stem cells.
description
2012 nî lūn-bûn
@nan
2012 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Modeling of catecholaminergic ...... nduced pluripotent stem cells.
@ast
Modeling of catecholaminergic ...... nduced pluripotent stem cells.
@en
Modeling of catecholaminergic ...... nduced pluripotent stem cells.
@nl
type
label
Modeling of catecholaminergic ...... nduced pluripotent stem cells.
@ast
Modeling of catecholaminergic ...... nduced pluripotent stem cells.
@en
Modeling of catecholaminergic ...... nduced pluripotent stem cells.
@nl
prefLabel
Modeling of catecholaminergic ...... nduced pluripotent stem cells.
@ast
Modeling of catecholaminergic ...... nduced pluripotent stem cells.
@en
Modeling of catecholaminergic ...... nduced pluripotent stem cells.
@nl
P2093
P921
P1476
Modeling of catecholaminergic ...... nduced pluripotent stem cells.
@en
P2093
Amira Gepstein
Bernard Belhassen
Ilanit Itzhaki
Irit Huber
Leonid Maizels
Lior Gepstein
Liron Miller
Michael Glikson
P304
P356
10.1016/J.JACC.2012.02.066
P407
P577
2012-06-27T00:00:00Z